Tiezheng Li

Title: Innovations of Tiezheng Li in Glycoengineering

Introduction

Tiezheng Li is a prominent inventor based in Columbia, MD (US), known for his significant contributions to the field of glycoengineering. With a total of four patents to his name, he has made remarkable advancements in the synthesis and remodeling of therapeutic antibodies.

Latest Patents

Among his latest patents, Tiezheng Li has developed recombinant Endo-S2 mutants, referred to as Endo-S2 glycosynthases. These mutants exhibit reduced hydrolysis activity and increased transglycosylation activity, which are crucial for synthesizing glycoproteins. This invention allows for the addition of desired sugar chains to fucosylated or nonfucosylated GlcNAc-IgG acceptors. The implications of this technology include enhanced biological activities such as prolonged half-life in vivo, reduced immunogenicity, and improved targeting abilities for therapeutic agents. Another notable patent involves a one-pot enzymatic approach for transglycosylation of endo-S and endo-S mutants, enabling chemoenzymatic synthesis of azido-tagged N-glycoforms of monoclonal antibodies.

Career Highlights

Tiezheng Li is affiliated with the University System of Maryland, where he continues to push the boundaries of research in glycoengineering. His work has garnered attention for its potential applications in therapeutic development and antibody engineering.

Collaborations

He collaborates with esteemed colleagues such as Lai-Xi Wang and Xin Tong, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Tiezheng Li's innovative work in glycoengineering exemplifies the intersection of science and technology, paving the way for advancements in therapeutic antibody development. His contributions are vital to the ongoing evolution of biopharmaceuticals.